Core Viewpoint - The article discusses the initiative by the Ministry of Industry and Information Technology and the Ministry of Agriculture and Rural Affairs of China to promote the innovation and development of non-grain bio-based materials, focusing on key technology innovation, application scenario expansion, and the cultivation of characteristic bases [1][4]. Group 1: Recommended Directions - The initiative emphasizes three main directions: key technology innovation, application scenario expansion, and characteristic base cultivation [2][4]. - Key technology innovation focuses on disruptive and leading technologies in areas such as industrial strains and enzyme protein components, non-grain biomass saccharification, and efficient purification of low-concentration products [2][5]. - Application scenario expansion targets the commercialization of bio-based materials in various products like household plastics, engineering plastics, and medical materials, validated in sectors such as logistics, hospitality, and agriculture [2][5]. - Characteristic base cultivation aims to develop industrial bases that effectively address the challenges of collecting and transporting non-grain biomass, contributing positively to regional economic development [2][5]. Group 2: Application Conditions - Eligible applicants include registered production enterprises, research institutions, and industrial parks in China, which must demonstrate sound management and compliance with safety and environmental standards [6]. - The cases submitted should possess high technical standards and complete solutions, with key technologies having independent intellectual property rights and being domestically leading [6]. - Application materials must be objective and truthful, providing real application cases and supporting documents [6]. Group 3: Recommendation Process - The recommendation process involves organizing applications at the provincial level, verifying and recommending cases, and ultimately promoting a selection of significant cases nationwide [6][7]. - Provincial departments will conduct a review of submitted cases and compile a recommendation summary to be sent to the Ministry of Industry and Information Technology [6][7]. - The Ministry will then promote these cases through various media channels and industry events to facilitate knowledge sharing and commercial cooperation [7]. Group 4: Support and Promotion - The initiative includes measures to enhance publicity for recommended cases through mainstream media and industry platforms, fostering experience exchange and collaboration [7]. - Policy support will be provided for the transformation and application of industrial results, including financial backing for relevant enterprises and projects [7]. - Local governments are encouraged to offer additional support for outstanding cases with replicable value, aiding in technology research and product promotion [7].

由Synbio深波主办的 Synbio China 第三届中国合成生物学"科学家+企业家+投资家"博 览 会 将于2025年8月1-2日在苏州国际博览中心举办（同期举办第七届CMC-China博览会）。 北京化工、上海交大、华东理工、浙大、重大、天工所等高校专家确认出席！ 微构工厂、河南生物产业集团、嘉必优、福瑞达、聚源生物、华康药业、锦波生物等企业专家确认出 席！ 扫描二维码 免费报名 大会议程 8月1日 院士与专家讲座 9:30-10:00 院士专家分享 嘉宾行程确认中 10:00-10:30 院士专家分享 嘉宾行程确认中 10:30-10:50 合成生物学产业化机遇与挑战 徐绚明 微构工场董事长 11:30-11:50 解锁非粮基生物质潜能：产业化发展的创新路径与实践探索 袁其朋 北京化工大学教授 10:50-11:10 合成生物力：驱动绿色原料新浪潮 嘉宾行程确认中 11:10-11:30 话题确认中 秦天苍 河南生物产业集团董事长 11:50-12:10 美妆新原料产业化的启示 嘉宾行程确认中 12:10-13:30 午休时间 8月1日 使能技术专场 13:30-13:50 生物制造技术的昨天、今天 ...

Project Overview - The project involves the establishment of a thousand-ton bio-based product production line, focusing on 1,3-PDO, calcium lactate, vanillin, and sialic acid processing [3] - The total investment for the project is 50 million yuan, with 5 million yuan allocated for environmental protection [3] - The production capacity upon completion will be 720 tons of 1,3-PDO, 940 tons of calcium lactate, 30 tons of vanillin, and 10 tons of sialic acid annually [3] Company Background - Si Peng Bio-materials (Nantong) Co., Ltd. is a wholly-owned subsidiary of Shanghai Si Peng Technology Co., Ltd., established in May 2022 [4] - The company focuses on negative carbon synthetic biology and is led by a team of scientists from Shanghai Jiao Tong University [4] - It has developed a unique one-step method for synthesizing polylactic acid (PLA) from carbon dioxide, achieving a 70% reduction in carbon emissions [4] - The company has partnered with Angel Yeast to establish a thousand-ton production line, with products including bio-based polyols and biodegradable plastics [4] Industry Insights - The bio-based materials sector is witnessing significant developments, with various companies making strides in bio-manufacturing technologies [8] - The market for bio-based materials is projected to grow substantially, indicating a competitive landscape for companies involved in this field [8]

Core Viewpoint - Synthetic biology and biomanufacturing are gaining significant attention and support from various sectors, including government, academia, and industry, highlighting their potential as new productive forces in the economy [1][17]. Event Overview - The SynBio China Third China Synthetic Biology "Scientists + Entrepreneurs + Investors" Expo will be held on August 1-2, 2025, at the Suzhou International Expo Center, featuring over 20,000 participants [3][33]. - The expo will include seven sub-conferences focusing on various aspects of synthetic biology, including health, food, and beauty industries [3]. Industry Challenges - Despite rapid dissemination of synthetic biology concepts in China, the industry faces challenges such as achieving scalable production, realizing product value, market exploration, and innovation in core competitiveness [17]. Applications and Innovations - Synthetic biology is driving innovations in functional ingredients, next-generation food additives, and personalized health foods, showcasing its transformative potential in the food industry [11][12]. - The technology is also advancing in the beauty sector, with applications in functional skincare ingredients and medical aesthetics [15][18]. Collaboration and Networking - The event aims to facilitate collaboration among innovators, industry experts, and investors, providing a platform for project promotion and industry guidance [20].

Core Viewpoint - The successful registration of medical-grade PHA microsphere materials by Zhuhai Maide Biological Technology Co., Ltd. marks a significant advancement in the standardization and regulation of domestic biomedical materials, providing new momentum for the development and industrialization of downstream medical device products [1][5]. Group 1: Main Document Registration - The main document registration system aims to streamline the registration process for medical devices by standardizing the quality data management of key raw materials [2]. - The registration of Maide Biological's medical-grade PHA microspheres will serve as a standardized raw material for Class III absorbable medical devices and drug delivery applications [2]. - Key benefits of the registration include lowering registration barriers, shortening review cycles, and ensuring controllable quality through comprehensive data on the physicochemical properties and biocompatibility of PHA microspheres [2]. Group 2: PHA as a Future Star in Biomedical Materials - Polyhydroxyalkanoates (PHA) are natural polymers synthesized by microorganisms, known for their biodegradability, biocompatibility, and customizable mechanical properties [3]. - PHA degrades into carbon dioxide and water in the body, promoting ATP production and aiding tissue repair, making it an ideal choice for implantable medical devices [3]. - Maide Biological has established a comprehensive technological barrier covering the purification, large-scale production, and end-use applications of medical-grade PHA [3]. Group 3: Core Patent and Production Capacity - The company has developed proprietary purification processes for medical-grade PHA, addressing batch stability issues and has applied for over 50 domestic and international patents [4]. - The production capacity has been upgraded with a thousand-ton production line in Zhanjiang, ensuring a stable supply of industrial-grade PHA and solidifying the supply chain for medical-grade materials [4]. Group 4: Industry Impact - The completion of the main document registration provides a high-standard raw material solution for medical device companies, promoting the independent development of high-end medical materials in China [5]. - Maide Biological aims to break the overseas technology monopoly through innovation, with the large-scale application of PHA microspheres expected to foster a new wave of domestic high-end medical devices in fields such as tumor intervention and aesthetic repair [5].

Core Viewpoint - The establishment of the Marine Biobased Materials Industry Alliance Research Institute represents a significant collaboration between academia and industry, aiming to advance the development of marine biobased materials through shared resources and expertise [3][4]. Group 1: Collaboration and Innovation - The Marine Biobased Materials Industry Alliance Research Institute is a deep collaboration involving universities, enterprises, and research institutions, leveraging academic research and market experience to promote the marine biobased materials industry [3]. - Qingdao University is a leading research institution in marine biobased materials, with significant advancements in polysaccharide fiber technology, providing essential support for the strength, flexibility, and environmental friendliness of seaweed fibers [3]. - Aimer Co., Ltd. has partnered with Qingdao University to optimize the performance of seaweed fibers and has participated in the formulation of national standards for textile analysis [3]. Group 2: Sustainability and Challenges - Marine biobased materials are gaining attention due to their renewable nature and environmental benefits, including natural degradation and reduced reliance on non-renewable resources [4]. - Despite their advantages, the marine biobased materials sector faces challenges such as limited raw material sources, high production costs, and the need for performance improvements [4]. - The establishment of the research institute aims to address these challenges through enhanced collaboration across the industry, contributing to carbon neutrality goals and supporting global sustainable development [4].

作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金 各方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投 资家，在产业发展中发挥着重要作用。 融行业智慧、共襄盛举 聚产业力量、擘画未来 SynBio China第三届中国合成生物学"科学家+企业家+投资家"博览会 将于2025年8月1-2日在 苏州国际博览中心B馆 举办（同期举办 第七届CMC-China博览会 ）！ 本次博览会共包含7个子会议： 第三届中国合成生物学"科学家+企业家+投资家"大会 SynBio China合成生物学与食品大健康产业大会 中国蛋白生物制造大会 美之原·合成生物学功能护肤大会 美之注·注射医疗美容产业大会 SynBio China合成生物学产学研对接会 SynBio China合成生物学新锐项目路演 诚邀莅临，共襄盛举 展会名称： Synbio China 第三届中国合成生物学"科学家+企业家+投资家"博览会 展会 时间： 2025年8月1-2日 主办单位： synbio深波 支持单位： synbio新农食、synbio新美护、synbio新材料、synbio合成生 ...

Core Viewpoint - Synthetic biology and biomanufacturing are gaining significant attention and support from various sectors, including government, academia, and industry, highlighting their potential as new productive forces in the economy [1][17]. Event Overview - The SynBio China Third China Synthetic Biology "Scientists + Entrepreneurs + Investors" Expo will be held on August 1-2, 2025, at the Suzhou International Expo Center, featuring over 20,000 participants [3][33]. - The expo will include seven sub-conferences focusing on various aspects of synthetic biology, including health, food, and beauty industries [3]. Industry Challenges - Despite rapid dissemination of synthetic biology concepts in China, the industry faces challenges such as achieving scalable production, realizing product value, market exploration, and innovation in core competitiveness [17]. Applications and Innovations - Synthetic biology is driving innovations in functional ingredients, next-generation food additives, and personalized health foods, showcasing its transformative potential in the food industry [11][12]. - The technology is also being applied in the beauty sector, with advancements in recombinant collagen and bioactive ingredients for skincare [15][18]. Collaboration and Networking - The event aims to facilitate collaboration among innovators, industry experts, and investors, providing a platform for project promotion and industry guidance [20].

Core Viewpoint - The establishment of a new material project in Anxiang County, Hunan, marks a significant step towards developing a non-grain raw material synthetic biology manufacturing industry, with an annual production capacity of 50,000 tons of new materials [1][3]. Group 1: Project Overview - The project focuses on producing cellulose polylactic acid (PLA) using non-grain raw materials such as reeds and straw, which are ideal for bio-manufacturing [3]. - The synthetic biology method will decompose cellulose and hemicellulose from reeds into glucose and xylose, which will then be fermented into lactic acid and polymerized into biodegradable plastics [3]. - The biodegradable plastic produced can decompose completely into carbon dioxide and water within 6 to 12 months after disposal [3]. Group 2: Market and Industry Context - The bio-based raw materials are categorized into grain-based and non-grain-based, with non-grain options like reeds offering significant advantages in cost, energy savings, and carbon reduction compared to grain-based products [3]. - Anxiang County has over 20,000 acres of reeds, primarily located along the Li River, Songzi River, and west of the Hudu River, providing a solid foundation for the synthetic biology industry [3]. - The collaboration with Shanghai Hanhe Biological New Materials Technology Co., Ltd. strengthens Anxiang County's position in the synthetic biology sector [3].

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由作者重新编写，仅作新材料相关领域介绍，本文 不构成任何投资建议！转载请注明来源！ 5月20日， 凯赛生物 在投资者互动平台上表示， 目前公司位于山西合成生物产业园的项目建设正在进 行中，受园区配套基础设施规划变动影响，公司年产90万吨生物基聚酰胺项目有所延期， 但项目的一 部分—— 年产5000吨生物基高温聚酰胺生产线 已经建成，可满足目前连续纤维复合材料开发的需求 。 公司在合肥规划建设的 Bio-PPA CFRT生产基地 也已经开始建设。 关于凯赛生物山西合成生物产业园项目 据了解，凯赛生物与山西综改示范区管委会于 2020年10月签署合作协议，合力打造"山西合成生物产业 生态园"，计划 总投资规模为800亿元 ，其中一期投资计划投资450亿元，二期计划投资 350 亿元。 核心项目 包括240万吨玉米深加工项目及 500 万吨 / 年生物发酵液项目、年产 50 万吨生物基戊二胺项 目、年产 90 万吨生物基聚酰胺项目和年产 8 万吨生物基长链二元酸项目（含 4 万吨生物法癸二酸项 目）。达产后产值将达千亿元以上。 项目详情： 凯赛 ...